A New Tool for In Vivo Study of Astrocyte Connexin 43 in Brain. by Droguerre, M. et al.
1Scientific RepoRtS |         (2019) 9:18292  | https://doi.org/10.1038/s41598-019-54858-9
www.nature.com/scientificreports
A new tool for In Vivo Study of 
Astrocyte Connexin 43 in Brain
Marine Droguerre1,7, Tomokazu tsurugizawa2,7, Adeline Duchêne1, Benjamin Portal  3, 
Bruno P. Guiard3, Nicole Déglon  4,5, Nathalie Rouach6, Michel Hamon1, Franck Mouthon1, 
Luisa ciobanu2* & Mathieu Charvériat  1*
Astrocytes are glial cells organized in dynamic and structured networks in the brain. These plastic 
networks, involving key proteins such as connexin 43 (Cx43), are engaged in fine neuronal tuning 
and have recently been considered as emerging therapeutic targets in central nervous system 
disorders. We developed and validated a new application of the manganese-enhanced magnetic 
resonance imaging (MEMRI) technique allowing in vivo investigations of astrocyte-neuron interactions 
through quantification of brain Cx43 functional activity. The proof of concept has been achieved by 
quantification of MEMRI signals in brain after either local astrocyte-specific Cx43 knockdown with 
shRNA or systemic administration of Cx43 blockers. Unilateral hippocampal Cx43 genetical silencing 
was associated with an ipsilateral local increase of MEMRI signal. Furthermore, Cx43 blockers also 
enhanced MEMRI signal responses in hippocampus. Altogether, these data reveal the MEMRI technique 
as a tool for quantitative imaging of in vivo Cx43-dependent function in astrocytes under physiological 
and pathological conditions.
Data accumulated over the last decades mainly point out a role for glial cells in providing neurons with metabolic, 
structural and trophic support1. However, recent data have also shown that astrocytes are key non-neuronal cells 
involved in active signaling contributing to brain functions, as they notably regulate sleep-wake cycle, cognition2 
and behavior3. At the cellular level, neuronal activity is tuned by astrocytes, in particular at tripartite synapses, 
that associate pre- and postsynaptic structures with an astroglial element4. Furthermore, astrocytes are organized 
in tightly regulated plastic networks5, through the transmembrane proteins connexins (Cx), especially connexin 
43 (Cx43), which form hemichannels and gap junction channels6. A large body of evidence already shows that 
these networks are involved in neuronal modulation and play important roles in brain functions3,7–9.
To date, only few imaging markers of astrocytes such as positron emission tomography (PET) probes10, pas-
sive fluorescent dyes11 and genetically encoded calcium ions (Ca2+) indicators12, have been developed and suc-
cessfully used. However, the in vivo usefulness of these probes is limited due to the requirement of their local 
intracerebral application13. In vivo brain imaging of the interactions between astrocytes and neurons is hence still 
challenging. We herein report data showing that manganese-enhanced magnetic resonance imaging (MEMRI) 
can capture those interactions. Indeed, previous findings using MEMRI suggest that: (i) manganese enters both 
neurons and astrocytes in brain14, (ii) astrocytes concentrate 80% of cerebral manganese ions (Mn2+)15, and (iii) 
Mn2+ shares chemical similarities with Ca2+, thus being able to enter neurons and astrocytes through Ca2+ chan-
nels and Na+/Ca2+ exchangers14. Accordingly, glial activation, notably during neuro-inflammatory processes16, 
neuronal tract tracing, and other specifically neuronal features could be studied using MEMRI. In our study, we 
developed and validated a new application of the MEMRI technique allowing the direct in vivo investigation of 
astrocyte-neuron interactions through quantification of hippocampus Cx43 functional activity. To this goal, we 
used in vivo administration of recombinant lentivirus targeting Cx43 expression and systemic treatments with 
known connexin modulators in mice.
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Materials and Methods
Animals. Experiments were performed on 42 wild-type C57BL/6 male mice. Mice were housed 4–5 per cage 
under standard conditions (12/12 h light-dark cycle, light on at 7 am, 22 ± 1 °C ambient temperature, 60% rela-
tive humidity). Animal surgery and experimentations conducted in this study were approved by (i) the French 
Minister (Ministère de l’Education Nationale, de l’Enseignement Supérieur de la Recherche; France) and (ii) the 
local ethics committee (Comite ́ d’Ethique en Expe ́rimentation Animale, Commissariat à l’Energie Atomique 
et aux Energies Alternatives, Direction des Sciences du Vivant; Fontenay-aux-Roses, France) under reference: 
APAFIS#4082-2016021510499450v2). Experiments were conducted in strict accordance with the recommenda-
tions and guidelines of the European Union (Directive2010/63/EU) and the French National Committee (Décret 
2013-118). All efforts were made to improve animal welfare and minimize animals suffering.
Drugs and treatments. Mefloquine (MEF; Sigma-Aldrich), meclofenamic acid (MFA; Sigma-Aldrich) and 
flecainide acetate (FLE; Sigma-Aldrich) were freshly prepared in 0.9% NaCl with 2% DMSO and administered 
intraperitoneally (i.p.) at the same dose of 1 mg/kg in a volume of 5 mL/kg, 2.5 h before imaging. Control animals 
received the vehicle only under the very same conditions.
Preparation and stereotaxic injection of lentiviral vectors. MOKOLA pseudotyped lentiviral vector 
(LV) encoding a shRNA directed against Cx43 (passenger-loop-guide strand: AACAGTCTGCCTTTCGCTGTA- 
TAGTGAAGCCACAGATGTA-TACAGCGAAAGGCAGACTGTT) or GFP (passenger-loop-guide strand: 
GCAAGCTGACCCTGAAGTTCAT-CTGTGAAGCCACAGATGGG-ATGAACTTCAGGGTCAGCTTGC) 
mRNA (control vector; shCTRL-LV) within astrocytes were generated as previously described17,18. For these 
recombinant viruses, the viral envelope ensures the specific tropism towards astrocytes. In addition, a detarget-
ing strategy using miR9*T and miR124T was set up to eliminate any possible residual expression in neuronal 
cells17–19.
Mice were anesthetized with ketamine 75 mg/kg i.p. and xylazine 10 mg/kg i.p. LV were injected using a 
34-gauge blunt-tip needle connected to a Hamilton syringe (Reno) with a polyethylene catheter. Dilutions of viral 
preparations in PBS containing 1% bovine serum albumin (BSA) were made so as to reach a final concentration 
of 100,000 ng p24 µL−1 in the suspensions for injections. Mice received unilateral injections of 1 µL LV suspension 
at a rate of 0.1 µL/min at three different sites into the hippocampus. ShCx43-LV was injected on one side (either 
right or left, randomly chosen) and shCTRL-LV was injected on the contralateral side (left or right, respectively) 
in each mouse. The stereotaxic coordinates for these three unilateral injections were respectively: site 1 = AP, 
−1.94; L, ± 2.00 and V, −1.50; site 2 = AP, −2.46; L, ± 2.50 and V, −2.60; site 3 = AP, −3.0; L, ± 2.7 and V, −3.5 
(in mm from bregma20). At the end of each injection, the needle was left in place for 5 min before being slowly 
removed. At the end of the injection procedure, the skin was sutured with 4-0 silk thread (Mersilkä, Ethicon Inc.) 
and mice were allowed to recover under a heating light before returning in their home cage.
MRI acquisitions. The MEMRI technique is based on the paramagnetic properties of Mn2+ which induce a 
marked reduction of the longitudinal T1 relaxation time during MRI. MRI signal acquisitions were performed on 
horizontal bore small animal scanners (Bruker BioSpin, Ettlingen, Germany) operating at 7 T and 11.7 T using a 
4-channel mouse brain array coil and a two-channel mouse brain cryoprobe, respectively. The mice were anes-
thetized with 0.5–1.0% isoflurane in air throughout the experiments. The respiration rate was monitored and 
the body temperature was maintained at 37 °C using an MR-compatible, feedback-controlled air heating system 
(model 1025; SA Instruments, NY) or circulating hot water system. A capillary filled with 100 µM MnCl2 (in dis-
tilled water) was placed on the side of the head, inside the radiofrequency (RF) coil, and was used as reference for 
T1-weighted signal intensity normalization.
The T1-weighted images were acquired using a 3D rapid acquisition with relaxation enhancement (RARE) 
sequence: RARE factor 4, repetition time/echo time = 250 ms/6 ms, 4 averages. For T1 relaxation time measure-
ments, we used a true Fast Imaging with Steady-state free Precession (trueFISP) sequence with the following 
acquisition parameters: repetition time/echo time = 3.66/1.83 ms, flip angle = 10, inversion time = 80 ms, number 
of inversion times = 60, 2 averages. The spatial resolutions and acquisition times for the two sequences on the two 
MRI systems are listed in Table 1.
Data processing. The position of the brain image was co-registered to a template using SPM8 software 
(Welcome Trust Center for Neuroimaging, UK). The template image was co-registered to mouse brain atlas20. 
T1-weighted signals were normalized using the signal intensity from the reference tube. T1 maps were calculated 
as described previously21. Eighteen regions of interest (ROIs) were defined using the mouse brain atlas. The aver-
aged T1-weighted signals and T1 values were calculated using an in-house written Matlab program. To compen-
sate for differences in coil sensitivity between left and right channels, we calculated the signal intensities in ROIs 
drawn in the left and right cerebral cortex, including the somatosensory cortex and insular cortex (ROIcortex_left 
Acquisition 
time (min) Spatial resolution
7 T 11.7 T 7 T 11.7 T
RARE 80 47 0.1 × 0.1 × 0.1 mm3 0.1 × 0.1 × 0.1 mm3
FISP 60 70 0.15 × 0.15 × 0.15 mm3 0.1 × 0.1 × 0.1 mm3
Table 1. Data acquisition parameters for the two MRI devices (7 T and 11.7 T). RARE, 3D Rapid Acquisition 
with Relaxation Enhancement; FISP, Fast Imaging with Steady-state free Precession.
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Figure 1. MEMRI signal responses to selective Cx43 knockdown expression in the mouse hippocampus. (A) 
Experimental timeline used for the experiments shown in E, G and Table 2. Mice received intra-hippocampal 
shRNA injections and were allowed to recover for 14 days. On day 15, MnCl2 (50 mg/kg) was delivered i.p. and 
MEMRI signal acquisition was performed 24 h later. (B) shRNA stereotaxic injection procedure. Mice received 
unilateral injections of LV suspension at three different sites into the hippocampus. ShCx43-LV was injected 
on one side and shCTRL-LV on the contralateral side (C) Representative fluorescence microscopy images of 
hippocampal shCTRL-LV- and shCx43-LV-injected sides showing DAPI (blue), GFAP+ cells (green) and Cx43 
expression (red). Arrow heads point at typical double-labeled GFAP+/Cx43+ astrocytes (top; shCTRL-LV) 
or highlight the dramatic decrease in the hippocampal expression of Cx43 (bottom; shCx43-LV injected 
hippocampus). Scale bar: 20 µm. (D) Relative expression of Cx43 in the hippocampus on the shCTRL-LV versus 
the shCx43-LV-injected side. ***p < 0.001, Mann-Whitney test. Each bar is the mean ± SEM of 9 independent 
determinations. (E) Typical MEMRI signal responses maps (T1) at hippocampal level (AP = −1.7 mm and 
−3.0 mm20) in a mouse injected with shCx43-LV on one side and shCTRL-LV on the other side. Cx, Cortex; 
CA1, 2, 3, respective regions of cornu ammonis; DG, Dentate Gyrus; D3V, Dorsal 3rd ventricle. (F) Respective 
T1 (in ms) and (G) T1-weighted signal intensity values in the hippocampus on shCTRL-LV and shCx43-LV 
injected side. MR acquisitions were performed on a 11.7 T Bruker imaging system. Significant differences in 
both parameter values were observed between the two sides; *p < 0.05, paired t test. (H) Experimental timeline 
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ROIcortex_right). The averaged T1-weighted signal intensity on the left side (SIleft) was then corrected following the 
equation:
= .SI SI
SI
SI_
_
_ (1)
left corrected left
cortex right
cortex left
Immunohistochemistry. After MRI acquisitions, mice were deeply anesthetized and transcardially per-
fused with 4% paraformaldehyde in phosphate-buffered saline (PBS). Series of one in twelve 30 μm thick coronal 
sections were incubated in a solution of rabbit anti-GFAP (1:500, Agilent technologies) and mouse anti-Cx43 
(1:250, BD transduction) overnight at 4 °C. Sections at the very injections sites and displaying signs of lesions 
were discarded. After several rinses in PBS containing 0.25% Triton-X100 (PBST), sections were incubated for 
2 h at room temperature in a mixture of Alexa Fluor® 488-conjugated highly cross-adsorbed donkey anti-rabbit 
and Alexa Fluor® 555-conjugated donkey anti-mouse (all at 1:500; Life technologies, ThermoFisher) antibodies 
in PBST supplemented with 10% normal donkey serum and 0.1% BSA. Sections were finally rinsed extensively 
and mounted onto slides, coverslipped using Mowiol® and stored at 4 °C.
On the other hand, coronal sections at hippocampal level from mice injected locally with shCx43-LV on one 
side and shCTRL-LV on the other side were labeled with the nucleic acid dye 4′6-diamidino-2-phenylindole 
(DAPI) to visualize all cell nuclei and verify that recombinant lentiviruses were devoid of any neurotoxic effect.
Quantification of Cx43 deletion. Cx43-immunolabeled hippocampi were pictured for each injection site 
using an Olympus BX-51 microscope equipped with Mercator Software (Explora Nova, France). The dentate 
gyrus area was framed at x40 magnification lens for each injection site. Quantification of Cx43-labeled sections 
was conducted with the FIJI software (ImageJ 2, NIH). Dentate gyri of the three injection sites sections were 
defined as the region of interest and a square (800 × 800 px) was delineated on each injection site to measure the 
mean gray value. Value intensity of Cx43 gray label was normalized to the GFAP gray label value in the very same 
area. Results are presented as the mean ± SEM of the three injection sites gray value.
Experimental design and statistical analyses. Animals were divided into three sets of experiments as 
described in the experiment timelines (Figs. 1A,H and 2A): LV intra-hippocampal injections only (Set A, n = 7); 
LV intra-hippocampal injections and vehicle or MEF i.p. administration (Set B, n = 11); vehicle, MEF, MFA or 
FLE i.p. administration (Set C, n = 24). In set A, animals were injected with MnCl2 50 mg/kg (in distilled water) 
i.p. two weeks after LV injections, and MRI acquisitions (see below) were performed 24 h later. In set B, mice 
were injected with LV and MnCl2 as in set A, then received MEF treatment 24 h after i.p. MnCl2 and 2.5 h before 
MRI acquisitions. In set C, mice received only MEF, MFA or FLE i.p. 24 h after i.p. MnCl2 and 2.5 h before MRI 
acquisitions.
Statistical analyses were performed using GraphPad Prism version 7.0c. Data were analyzed using 
Mann-Whitney non-parametric test, paired t test or one sample t test compared to the hypothetical value 1 or 100 
as appropriate. In each experiment, a level of p < 0.05 was accepted as evidence for a statistically significant effect 
(*p < 0.05; **p < 0.01; ***p < 0.001). Changes in MEMRI signal in response to the Cx43 expression knock-down 
and/or drugs administration are expressed as means ± SEM of percent of control. All other data are expressed as 
mean ± SEM. For analysis of MEMRI signal responses to drugs administration, quantification was made in six 
brain areas selected on the basis of their different response patterns.
Results
Selective silencing of astrocyte Cx43 expression in the mouse hippocampus. Recombinant LV 
with a glial tropism and expressing shRNA against Cx43 (shCx43-LV) were stereotaxically injected into one hip-
pocampus to generate mice with a unilateral specific inactivation of astroglial Cx43 in this region19. Recombinant 
LV expressing shRNA against GFP (shCTRL-LV) were injected into the contralateral hippocampus as control 
(Fig. 1B,C). DAPI labeling showed that the cell density in both hippocampi did not differ from each other and 
from that determined in control mice (not shown). The characteristic punctate Cx43-like immunoreactivity in 
shCTRL-LV injected hippocampus was shown to co-localize with GFAP-immunoreactive astrocyte (Fig. 1C). 
Quantification of immunostained brain sections confirmed that mice displayed a dramatic decrease in the hip-
pocampal expression of Cx43 on their shCx43-LV-injected side relative to their shCTRL-LV-injected contralat-
eral side (approx. −85%; p < 0.001; Mann-Whitney test; Fig. 1C,D).
MEMRI signal responses to selective Cx43 knockdown expression in the mouse hippocampus. 
Mn2+ accumulation, because of its ability to shorten the longitudinal relaxation time (T1) of the proton, produces 
hyperintense regions on T1-weighted images. To assess the impact of Cx43 knockdown on Mn2+ accumulation, 
we applied the MEMRI technique in shCx43-LV-injected mice which received MnCl2 via the i.p. route 24 h before 
used for the experiments shown in I and Table 3. Mice received intra-hippocampal shRNA injections and were 
allowed to recover for 14 days. On day 15, mice received MnCl2 (50 mg/kg; i.p.) then MEF (1 mg/kg; i.p.) or 
vehicle 24 h later. MEMRI signal acquisition was performed 2.5 h after the MEF administration. (I) Data are 
presented as mean ± SEM of the ratio shCx43-LV/shCTRL-LV of MEMRI signal intensity in the hippocampus 
2.5 h after i.p. administration of MEF or its vehicle. *p < 0.05, one sample t test compared to the hypothetical 
value 1, n = 6 in each group.
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the MEMRI acquisition. Figure 1E shows coronal T1 images of one representative mouse brain (−1.7 mm from 
bregma, left panel; −3.00 mm from bregma, right panel) 24 h after MnCl2 administration. A clear-cut decrease in 
MEMRI signal response appeared in the shCx43-LV injected hippocampus in comparison with the contralateral 
shCTRL-LV injected side (Fig. 1F). Quantification of images acquired with 7 T and 11.7 T MRI devices showed 
that T1 value for the hippocampus was significantly lower on the shCx43-LV injected side compared to the con-
tralateral shCTRL-LV injected side (−1.42 ± 0.53% and −5.31 ± 1.65% with 7 T and 11.7 T MR imaging systems, 
respectively, p < 0.05; paired t test, Table 2). On the other hand, a significant increase of the T1-weighted signal 
intensity was observed on the shCx43-LV injected side in comparison with the contralateral shCTRL-LV injected 
side (+15.20 ± 5.16% and +3.91 ± 1.24%, with 7 T and 11.7 T MR imaging systems, respectively; p < 0.05; paired 
t test) (Fig. 1G).
Quantification of MEMRI signal responses (T1, T1-w) in 17 supplementary brain regions from mice injected 
with recombinant LV showed that no significant difference between the shCx43-LV injected side and the con-
tralateral shCTRL-LV injected side was observed outside the hippocampus (Table 2). Thus, regardless the 
device on which the data were acquired: 7 T or 11.7 T, significant differences in the T1 relaxation time and the 
T1-weighted signal intensity were noted only at the hippocampal level (Table 2).
Mefloquine treatment normalized interhemispheric differences in MEMRI signal responses 
in shCx43-LV injected mice. Mice with unilateral selective silencing of Cx43 expression in hippocampal 
astrocytes received MnCl2 i.p. injection two weeks after intra-hippocampal LV administration, and were treated 
24 h later with MEF or vehicle i.p. 2.5 h before MEMRI signal acquisition (Fig. 1H). The ratio shCx43/shCTRL for 
T1-weighed intensity in the Cx43 knockdown hippocampus over that in the contralateral control hippocampus 
was compared to the theoretical value, i.e. 1, expected for equal values on both sides. In concordance with data 
obtained in the previous experimental series (Fig. 2G), the mean T1-weighted ratio was significantly different 
from 1 (n = 6; p < 0.05; one-sample t test) in unilateral Cx43 knockdown mice treated with the vehicle (Fig. 2I). 
In contrast, after MEF administration, no difference was found in hippocampal T1-weighted intensity between 
Figure 2. Effects of acute treatment with mefloquine (MEF), flecainide (FLE) or meclofenamic acid (MFA) 
versus vehicle (Veh) on MEMRI signal intensity in the mouse hippocampus. (A) Experimental timeline used 
for the experiments shown in B and C. Mice were injected with MnCl2 (50 mg/kg; i.p.) then received connexin 
blocker (MEF, FLE or MFA, all at 1 mg/kg i.p.) or vehicle 24 h later. MEMRI signal acquisition was performed 
2.5 h after the latter injection. (B) T1-weighted signal intensity maps in the hippocampus (AP = −1.7 mm20) 
after vehicle or mefloquine administration. (C) Mice pretreated with MnCl2 were subjected to MEMRI 2.5 h 
after administration of each drug. MEMRI signal intensity in the hippocampus was compared to the respective 
value in vehicle-treated control mice. Data are presented as mean ± SEM. Cx, Cortex; CA1, 2, 3, respective 
regions of cornu ammonis; DG, Dentate Gyrus; D3V, Dorsal 3rd ventricle. *p < 0.05, **p < 0.01, n = 6 in each 
group.
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Region
Signal changes for shCx43-LV vs. shCTRL-LV (%) Statistics
7 T 11.7 T 7 T 11.7 T
T1 T1-w T1 T1-w T1 T1-w T1 T1-w
Hip −1.42 ± 0.53 15.2 ± 5.16 −5.31 ± 1.65 3.91 ± 1.24 <0.05 <0.05 <0.05 <0.05
SC 0.40 ± 0.57 9.32 ± 6.58 −2.61 ± 4.91 3.12 ± 3.57 0.52 0.32 0.53 0.40
Cpu −0.34 ± 0.49 10.3 ± 6.99 −3.08 ± 4.89 −0.69 ± 4.19 0.54 0.33 0.41 0.84
DRa 1.09 ± 1.56 8.67 ± 7.24 1.13 ± 5.09 0.67 ± 5.13 0.56 0.54 0.95 0.91
Hyp 0.59 ± 1.62 8.20 ± 7.65 −2.48 ± 4.58 3.59 ± 5.21 0.81 0.63 0.41 0.62
LC 0.52 ± 1.18 10.7 ± 6.20 −2.10 ± 3.68 −1.01 ± 4.13 0.66 0.22 0.46 0.86
LPB −0.83 ± 1.14 13.7 ± 7.04 −6.56 ± 5.57 −2.00 ± 4.47 0.47 0.09 0.20 0.74
MC 0.58 ± 0.51 9.34 ± 6.57 −4.30 ± 3.81 0.47 ± 3.78 0.33 0.37 0.28 0.82
OB −0.07 ± 0.39 9.61 ± 8.10 −5.88 ± 5.16 2.27 ± 5.27 0.76 0.60 0.26 0.86
SN −0.85 ± 1.05 14.2 ± 6.74 −5.93 ± 5.96 0.54 ± 4.02 0.46 0.13 0.28 0.77
ThN −0.23 ± 0.54 13.1 ± 6.72 −3.39 ± 2.92 −0.85 ± 4.40 0.68 0.21 0.23 0.86
OC −0.42 ± 1.12 9.85 ± 7.68 −3.98 ± 5.06 0.75 ± 4.45 0.72 0.45 0.39 0.96
PrL 0.93 ± 1.87 7.59 ± 9.92 −2.36 ± 4.76 7.45 ± 6.93 0.70 0.68 0.51 0.48
AC −1.10 ± 0.84 13.4 ± 12.9 4.32 ± 6.91 6.60 ± 9.03 0.25 0.32 0.78 0.56
IC −0.16 ± 0.64 11.3 ± 9.44 −3.39 ± 9.06 4.15 ± 2.13 0.77 0.29 0.49 0.12
Cg −0.29 ± 1.45 7.77 ± 9.06 −3.97 ± 3.83 1.19 ± 5.16 0.81 0.60 0.33 0.82
mPFC 0.56 ± 1.10 7.17 ± 9.83 −0.14 ± 5.57 4.34 ± 6.28 0.61 0.72 0.83 0.69
Sep −1.41 ± 1.17 11.4 ± 8.20 −7.57 ± 7.73 2.11 ± 4.94 0.31 0.44 0.28 0.75
Table 2. Effects of astroglial Cx43 expression knockdown in the hippocampus on MEMRI signal in various 
brain regions. MEMRI signal response (T1 and T1-w, means ± SEM) in each brain region was compared in 
the shCx43-LV-injected side versus the shCTRL-LV-injected side in each mouse (paired t test). Abbreviations: 
SC, Somatosensory cortex; Cpu, Caudate putamen; Dra, Dorsal raphe pallidus; Hip, Hippocampus; Hyp, 
Hypothalamus; LC, Locus coeruleus; LPB, Lateral parabrachial nucleus; MC, Motor cortex; OB, Olfactory bulb; 
SN, Substantia nigra; ThN, Thalamic nuclei; OC, Orbital cortex, PrL, Prelimbic cortex; AC, Auditory cortex; IC, 
Insular cortex; Cg, Cingulate cortex; mPFC, Medial prefrontal cortex; Sep, Septum.
Region
Ratio T1-w Statistics
shCx43-LV/shCTRL-LV
shCx43-LV/
shCTRL-LV
Veh MEF Veh MEF
Hip 1.15 ± 0.05 1.06 ± 0.10 <0.05 0,56
SC 1.09 ± 0.07 1.04 ± 0.16 0.22 0.79
Cpu 1.10 ± 0.07 1.05 ± 0.16 0.20 0.75
DRa 1.09 ± 0.07 1.08 ± 0.19 0.28 0.71
Hyp 1.08 ± 0.08 1.09 ± 0.20 0.33 0.67
LC 1.11 ± 0.06 1.06 ± 0.13 0.15 0.67
LPB 1.14 ± 0.07 1.07 ± 0.12 0.11 0.58
MC 1.09 ± 0.07 1.03 ± 0.17 0.21 0.85
OB 1.10 ± 0.08 1.08 ± 0.18 0.29 0.68
SN 1.14 ± 0.07 1.07 ± 0.13 0.090 0.60
ThN 1.13 ± 0.07 1.07 ± 0.16 0.11 0.70
OC 1.10 ± 0.08 1.08 ± 0.19 0.26 0.71
PrL 1.08 ± 0.10 1.10 ± 0.24 0.48 0.70
AC 1.13 ± 0.13 0.97 ± 0.14 0.35 0.86
IC 1.11 ± 0.09 1.03 ± 0.16 0.29 0.88
Cg 1.08 ± 0.09 1.07 ± 0.21 0.43 0.74
mPFC 1.07 ± 0.10 1.08 ± 0.22 0.50 0.74
Sep 1.11 ± 0.08 1.09 ± 0.19 0.22 0.66
Table 3. Effects of mefloquine (MEF) treatment on MEMRI signal in various brain regions of mice with 
unilateral hippocampal Cx43 silencing. In both MEF- and vehicle (Veh)-treated mice, data are expressed as 
the ratio of MEMRI signal intensity in each brain area on the shCx43-LV-injected side over the shCTRL-LV-
injected side. Statistical analyses were made by comparing each ratio (mean ± SEM) with the hypothetical 
value 1. Abbreviations: SC, Somatosensory cortex; Cpu, Caudate putamen; Dra, Dorsal raphe pallidus; Hip, 
Hippocampus; Hyp, Hypothalamus; LC, Locus coeruleus; LPB, Lateral parabrachial nucleus; MC, Motor cortex; 
OB, Olfactory bulb; SN, Substantia nigra; ThN, Thalamic nuclei; OC, Orbital cortex, PrL, Prelimbic cortex; AC, 
Auditory cortex; IC, Insular cortex; Cg, Cingulate cortex; mPFC, Medial prefrontal cortex; Sep, Septum.
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the ShCx43-LV-injected side and the contralateral shCTRL-LV injected side (n = 5; p = 0.562; ns; one-sample t 
test, Fig. 2I). Quantification of T1-weighted ratio of MEMRI signal intensity in Cx43-LV-injected side over that in 
the contralateral shCTRL-LV-injected side showed that none of the same 17 brain regions as those selected - in 
addition to the hippocampus - in the previous experimental series presented any significant difference in MEF- 
versus vehicle-treated mice (Table 3).
MEMRI signal responses to Cx43 blockers in mouse hippocampus. We then investigated the 
effect, in vivo, of three pharmacological blockers of Cx43, MEF, MFA and FLE on MEMRI signal in the hip-
pocampus of intact healthy mice (without intra-hippocampal LV injections) that had received MnCl2 via the 
i.p. route 24 h before (Fig. 2A). Figure 2B showed the MEMRI signal intensity of selected coronal sections (both, 
−1.7 mm from bregma) of a representative vehicle-treated mouse (left panel) in comparison with a MEF-treated 
mouse (right panel). These images show a clear-cut increase in hippocampal MEMRI signal after MEF treat-
ment. Quantification of T1-w signal intensity in 6 mice in each group demonstrated that MEF-induced increase 
was statistically significant (+18.0 ± 6.0%, p < 0.05). As shown in Fig. 2C, both FLE and MFA also significantly 
increased the T1-w signal intensity in the mouse hippocampus, up to the same level as that found with MEF 
(FLE: + 18.0 ± 4.7%, p < 0.05; MFA: + 18.0 ± 4.3%, p < 0.01).
Discussion
Data from this study present a new application of MEMRI to investigate the functional activity of cerebral astro-
glial Cx43 in vivo, and to determine the effects of pharmacological blockers of astroglial Cxs in the mouse brain.
Neurons have long been considered as the primary performers of brain processes. However, during evolution, 
glia-to-neuron ratio significantly increases towards more and more adapted species. Among glial cells, astrocytes 
are closely connected to neurons and interactions between these two types of cells have largely been described22. 
Astrocytes have been successfully labeled with PET probes such as 11C-acetate23, 11C-DED and 11C-Sch22533610, 
passive fluorescent dyes such as sulforhodamine 10111 or genetically encoded Ca2+ indicators (GECIs)12. However, 
neurons, as well as astrocytes, readily take up blood-born lactate24, and so far, the use of GECIs or dyes has 
been limited due the requirement of their local intracerebral application and the low penetrance depth of optical 
microscopy13. In vivo brain imaging of the interactions between astrocytes and neurons is hence still challenging.
The functional activity of astrocyte networks involves key transmembrane proteins called Cxs5. Eleven Cx 
isoforms have been detected in the brain, and, among them, astrocytes express Cx43 and Cx30 isoforms in adult 
brains. While Cx30 is abundantly present in the thalamus, Cx43 and Cx30 are expressed at similar levels in the 
hippocampus6,25. The coupling between astrocytes is significantly reduced in cells lacking Cx43, demonstrating that 
this isoform is a major support for direct intercellular communication in astrocytes, notably in the hippocampus6,26. 
Additionally, Cx43-mediated networks have been shown to play an important role in several neuronal modulation 
processes2,6–8,27. In the present study, aimed at evaluating the role of Cx43 in Mn-based imaging, we silenced Cx43 
expression in the hippocampus on one side and used the contralateral hippocampus as control. Unilateral Cx43 
knockdown was achieved by intra-hippocampal injection of a lentiviral recombinant vector, shCx43-LV, pseudo-
typed with the MOKOLA envelop, and encoding a shRNA directed against Cx43 RNA within hippocampal astro-
cytes but not hippocampal stem cells or neurons17,18. Immunohistochemical controls fully confirmed that extinction 
of Cx43 expression occurred in astrocytes of the (randomly left or right) hippocampus injected with shCx43-LV. In 
contrast, Cx43 expression was preserved in the contralateral hippocampus injected with the control recombinant 
virus, shCTRL-LV, encoding non-relevant shRNA (shRNA against GFP). Interestingly, semi-quantitative estimates 
of DAPI labeling showed that none of these recombinant viruses had neurotoxic effects.
To compare the Mn-enhanced MR signal intensity in both sides of the hippocampus, as well as in other brain 
regions, LV-injected mice were administered MnCl2 i.p. 24 hours before imaging, i.e. under time conditions allowing 
Mn2+ concentration and distribution to reach equilibrium in brain28. The MnCl2 dose (50 mg/kg i.p.) was chosen 
to avoid any neurological symptoms or neurotoxicity29. MEMRI analyses on both hippocampal sides indicated that 
T1 was significantly shortened when Cx43 expression was inhibited. T1-weighted signal confirmed this observation 
within the hippocampus. In contrast, MEMRI analyses in the other 17 brain regions examined did not reveal any 
difference between the shCx43-LV injected side and the contralateral shCTRL-LV injected side. These data indicate 
that manganese was more concentrated only in the hippocampus where Cx43 expression was silenced14,30. There 
are two possible explanations for this differential manganese accumulation between the two hippocampi: (i) Mn2+ 
accumulates more in astrocytes on the shCx43-LV injected side as a result of a reduced diffusion through deficient 
gap junctions or decreased release caused by the lower density of Cx43 hemichannels or (ii) Mn2+ accumulates more 
in neurons as a functional consequence of Cx43 downregulation in astrocytes. As a matter of fact, although Mn2+ 
accumulation specifically in astrocytes, neurons, or other cells cannot be determined with the presently available 
methods, our study reveals that down regulation of Cx43 selectively in hippocampal astrocytes leads to changes in 
the local MEMRI signal and provides a first in vivo validation of a functional role for astrocyte Cx43 using whole 
brain imaging. Noteworthy, similar results were obtained with 7 and 11.7 Tesla fields, widening the potential applica-
tions of MEMRI using different types of equipment. Validation in other brain areas, with different expression levels 
of Cx43, such as cortex or striatum31, might also be interesting, especially regarding regional molecular heteroge-
neity of hemichannels and gap junctions involved in astrocyte-neuron interactions32. The respective contribution 
of hemichannels or gap junctions in the transport of manganese remains an important issue, which is, however, 
complex to evaluate due to the lack of specific in vivo tools. Interestingly, using a cell line derived from normal adult 
human osteoblasts, Romanello et al.33 highlighted that hemichannels participated in Mn2+ uptake from the external 
medium. On the other hand, Niessen et al.34 demonstrated that Mn2+ had the ability to diffuse within monolayers 
of transfected HeLa cells expressing murine Cx26, Cx32 as well as Cx43. These two series of data support the idea 
that both hemichannels and gap junctions are involved in manganese transport within adjacent cytoplasms and/or 
between cytoplasm and extracellular space.
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Although in vitro studies on cultured astrocytes led Lu et al.35 to report that Cx43 expression could be affected 
by Mn2+, the cation concentration required for this effect, 125–1000 μM, was higher than that which was probably 
reached in brain under our in vivo conditions, i.e. 24 h after a unique injection of MnCl2 at 50 mg/kg. With such 
conditions, available literature data on brain accumulation of peripherally injected MnCl236,37 led us to estimate 
that Mn2+ did not exceed 50 µM at the time of MEMRI signal acquisition. Even if direct measurements of brain 
Mn concentration will be needed to definitively exclude any possible alteration in Cx43 expression, it has to be 
emphasized that such alteration would occur equally in both hippocampi. Since our analyses consisted of com-
paring the hippocampus on the shCx43-LV-injected side with that on the contralateral shCTRL-LV-injected side, 
any global change in brain Cx43 caused by Mn2+ would not challenge the meaning of our data.
The next step for further investigations on the in vivo functional role of astrocyte Cx43 would be to quantify 
MEMRI signal in response to Cx43 up regulation specifically in astrocytes in the mouse hippocampus. However, 
to date, recombinant LV for Cx43 overexpression specifically in astrocytes are still under development and are 
not yet available for such studies.
It is well established that MEF inhibits Cx43-mediated functions, through gap junctions38,39 and hemichan-
nels40, potentially via loop gating41. Interestingly, in naive healthy mice, MEF significantly increased the MEMRI 
signal in the hippocampus, supporting the idea that in Cx43 knock-down animals, MEF concealed the disequi-
librium in MEMRI signal between both hippocampi by increasing the signal on the shCTRL-LV injected side up 
to that already achieved by Cx43 knockdown on the shCx43-LV injected side. Interestingly, the other two drugs 
tested, FLE and MFA, which are known to cross the brain-blood barrier and exert clear-cut inhibitory effects on 
Cx43 (but through still uncharacterized mechanisms)42,43, similarly increased MEMRI signal in the hippocam-
pus in naive healthy mice, further supporting the idea that MEMRI signal in this brain region is related to Cx43 
function.
Meanwhile, targeting Cxs, using in particular MEF, FLE and MFA, can result in changes in the properties 
of CNS drugs, in terms of pharmacological profiles40,42. Such techniques as MEMRI may help determining the 
mechanism of action of pharmacological combinations of CNS drugs with Cx targeted compounds, notably in 
terms of localization of Cx modulations in brain. Indeed, Cx expression displays regional heterogeneity within 
and between brain regions9. Furthermore, Cx functions can also be differentially regulated by local and region 
specific modulators such as neurotransmitters9. Interestingly, in our study, MEF restored equilibrium of the T1 
relaxation time of MEMRI signal between both hippocampi in mice injected with shCx43-LV on one side and 
shCTRL-LV on the contralateral side, which provided a direct demonstration of an in vivo action of MEF on 
Cx43-mediated function in brain.
MEMRI has already been investigated in humans, notably with the use of FDA-approved mangafodipir, a 
Mn2+ chelate with the ligand fodipir44. Translational application of the present study, possibly with the use of 
mangafodipir, might provide new insights into neuron-astrocyte interactions in clinical trials and constitute a 
new tool for pharmacological evaluation of new modulators of those interactions. Additionally, as Cx43 expres-
sion is altered in neurodegenerative disorders such as Alzheimer’s disease5,45, Parkinson’s disease, Huntington’s 
disease, amyotrophic lateral sclerosis46,47 and multiple sclerosis5,48, as well as in psychiatric disorders such as 
depression18,49, Cx43 function evaluation using MEMRI might also be interesting for further pathophysiological 
investigations of those disorders. The diversity of Cx isoforms in the brains combined with their diverse functions 
should be further investigated to fully understand their roles in the brain.
Significance statement. Astrocytes are key non-neuronal cells implicated in many brain functions. These 
glial cells are organized in functional networks, mostly through connexin 43 (Cx43)-mediated gap junction chan-
nels. Astroglial networks are engaged in fine neuronal tuning and have recently been considered as emerging 
new therapeutic targets in CNS disorders. However, comprehensive understanding of the complex relationships 
between astrocytes and neurons in vivo is limited due to the lack of adequate imaging tools. Here, we demonstrate 
that manganese enhanced magnetic resonance imaging (MEMRI) is a promising technique for studying in vivo 
the function of astrocyte Cx43 and assessing the pharmacological profiles of Cx43 modulators.
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